Concepts (279)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Liver Cirrhosis | 20 | 2019 | 901 | 2.790 |
Why?
|
| Liver Transplantation | 19 | 2019 | 1131 | 2.400 |
Why?
|
| Glomerular Filtration Rate | 10 | 2023 | 567 | 1.680 |
Why?
|
| Hepatorenal Syndrome | 4 | 2018 | 30 | 1.570 |
Why?
|
| Waiting Lists | 8 | 2020 | 242 | 1.390 |
Why?
|
| Liver Failure, Acute | 4 | 2015 | 96 | 1.380 |
Why?
|
| Kidney | 6 | 2019 | 1309 | 1.250 |
Why?
|
| Kidney Diseases | 4 | 2015 | 482 | 1.250 |
Why?
|
| Fasting | 2 | 2020 | 303 | 1.170 |
Why?
|
| Cystatin C | 4 | 2018 | 71 | 1.130 |
Why?
|
| Creatinine | 9 | 2023 | 402 | 1.050 |
Why?
|
| End Stage Liver Disease | 5 | 2020 | 189 | 0.960 |
Why?
|
| Kidney Function Tests | 2 | 2017 | 137 | 0.940 |
Why?
|
| Renal Insufficiency | 2 | 2018 | 252 | 0.800 |
Why?
|
| Liver | 6 | 2017 | 1799 | 0.760 |
Why?
|
| Metabolic Syndrome | 2 | 2020 | 363 | 0.700 |
Why?
|
| Factor VIIa | 6 | 2005 | 21 | 0.680 |
Why?
|
| Metabolomics | 3 | 2023 | 493 | 0.660 |
Why?
|
| Circadian Clocks | 1 | 2020 | 86 | 0.580 |
Why?
|
| Proteome | 1 | 2020 | 286 | 0.570 |
Why?
|
| Health Status Disparities | 2 | 2012 | 278 | 0.560 |
Why?
|
| Ascites | 2 | 2015 | 99 | 0.540 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2020 | 489 | 0.540 |
Why?
|
| Severity of Illness Index | 10 | 2019 | 3101 | 0.540 |
Why?
|
| Middle Aged | 32 | 2020 | 28886 | 0.510 |
Why?
|
| Liver Failure | 4 | 2017 | 90 | 0.500 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2017 | 131 | 0.490 |
Why?
|
| Liver Cirrhosis, Alcoholic | 3 | 2009 | 40 | 0.470 |
Why?
|
| Patient Discharge | 1 | 2019 | 506 | 0.470 |
Why?
|
| Biomarkers | 12 | 2023 | 3405 | 0.460 |
Why?
|
| Phosphodiesterase 5 Inhibitors | 1 | 2015 | 34 | 0.460 |
Why?
|
| Sildenafil Citrate | 1 | 2015 | 57 | 0.460 |
Why?
|
| Living Donors | 2 | 2014 | 116 | 0.450 |
Why?
|
| Tissue and Organ Procurement | 5 | 2019 | 253 | 0.440 |
Why?
|
| Acute Kidney Injury | 2 | 2019 | 686 | 0.440 |
Why?
|
| Renal Plasma Flow | 1 | 2014 | 4 | 0.430 |
Why?
|
| Renal Circulation | 1 | 2014 | 41 | 0.430 |
Why?
|
| Hepatitis C, Chronic | 5 | 2012 | 367 | 0.410 |
Why?
|
| Blood Coagulation Disorders | 3 | 2003 | 105 | 0.410 |
Why?
|
| Vascular Resistance | 1 | 2014 | 182 | 0.400 |
Why?
|
| Humans | 53 | 2023 | 131671 | 0.390 |
Why?
|
| Hemodynamics | 2 | 2014 | 816 | 0.390 |
Why?
|
| Arginine | 1 | 2015 | 344 | 0.380 |
Why?
|
| Adult | 25 | 2019 | 31717 | 0.370 |
Why?
|
| Fatty Liver | 3 | 2014 | 220 | 0.370 |
Why?
|
| Resource Allocation | 1 | 2012 | 52 | 0.360 |
Why?
|
| Male | 29 | 2020 | 65264 | 0.340 |
Why?
|
| Female | 32 | 2020 | 71181 | 0.340 |
Why?
|
| Kidney Transplantation | 3 | 2015 | 572 | 0.330 |
Why?
|
| Renal Insufficiency, Chronic | 2 | 2023 | 849 | 0.330 |
Why?
|
| Aged | 18 | 2019 | 21256 | 0.320 |
Why?
|
| Valproic Acid | 1 | 2010 | 161 | 0.320 |
Why?
|
| Polyethylene Glycols | 2 | 2008 | 245 | 0.310 |
Why?
|
| Interferon-alpha | 2 | 2008 | 241 | 0.310 |
Why?
|
| Liver Diseases | 2 | 2010 | 381 | 0.290 |
Why?
|
| Graft Rejection | 4 | 2019 | 560 | 0.280 |
Why?
|
| Interferons | 1 | 2008 | 136 | 0.270 |
Why?
|
| Hepatitis B | 2 | 2006 | 174 | 0.270 |
Why?
|
| Biological Specimen Banks | 1 | 2008 | 64 | 0.270 |
Why?
|
| Liver Neoplasms | 3 | 2009 | 1387 | 0.270 |
Why?
|
| HIV | 1 | 2008 | 179 | 0.250 |
Why?
|
| HELLP Syndrome | 1 | 2006 | 13 | 0.250 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2008 | 222 | 0.250 |
Why?
|
| Catheter Ablation | 1 | 2009 | 317 | 0.240 |
Why?
|
| Bile Ducts | 1 | 2006 | 53 | 0.240 |
Why?
|
| Risk Factors | 12 | 2019 | 10959 | 0.240 |
Why?
|
| Virus Activation | 1 | 2006 | 86 | 0.240 |
Why?
|
| Vasoconstrictor Agents | 2 | 2018 | 135 | 0.240 |
Why?
|
| Recombinant Proteins | 7 | 2008 | 1316 | 0.230 |
Why?
|
| Focal Nodular Hyperplasia | 1 | 2005 | 6 | 0.230 |
Why?
|
| Hemangioendothelioma, Epithelioid | 1 | 2005 | 10 | 0.230 |
Why?
|
| Hepatitis B virus | 1 | 2006 | 143 | 0.230 |
Why?
|
| Graft Survival | 4 | 2019 | 466 | 0.230 |
Why?
|
| Piperazines | 1 | 2007 | 272 | 0.220 |
Why?
|
| Hypertension, Portal | 1 | 2005 | 79 | 0.220 |
Why?
|
| Vena Cava, Inferior | 1 | 2005 | 99 | 0.210 |
Why?
|
| Tissue Donors | 2 | 2018 | 502 | 0.210 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2005 | 115 | 0.210 |
Why?
|
| Hepatocytes | 1 | 2005 | 234 | 0.210 |
Why?
|
| Time Factors | 6 | 2019 | 6279 | 0.210 |
Why?
|
| Survival Rate | 4 | 2019 | 2151 | 0.210 |
Why?
|
| Prochlorperazine | 1 | 2003 | 3 | 0.210 |
Why?
|
| Heparin | 1 | 2005 | 206 | 0.200 |
Why?
|
| Antiemetics | 1 | 2003 | 21 | 0.200 |
Why?
|
| Splenic Artery | 1 | 2003 | 24 | 0.200 |
Why?
|
| United States | 8 | 2017 | 11802 | 0.200 |
Why?
|
| Jehovah's Witnesses | 1 | 2003 | 17 | 0.200 |
Why?
|
| Pyrimidines | 1 | 2007 | 443 | 0.200 |
Why?
|
| alpha 1-Antitrypsin Deficiency | 1 | 2003 | 43 | 0.200 |
Why?
|
| Pilot Projects | 2 | 2020 | 1454 | 0.200 |
Why?
|
| Fibrinolytic Agents | 1 | 2005 | 200 | 0.200 |
Why?
|
| Venous Thrombosis | 1 | 2005 | 168 | 0.200 |
Why?
|
| Pericardiocentesis | 1 | 2003 | 17 | 0.200 |
Why?
|
| Treatment Outcome | 6 | 2018 | 12984 | 0.190 |
Why?
|
| Postoperative Complications | 3 | 2019 | 3130 | 0.190 |
Why?
|
| Intracranial Hemorrhages | 1 | 2003 | 79 | 0.190 |
Why?
|
| Biopsy, Needle | 1 | 2003 | 216 | 0.190 |
Why?
|
| Hepatitis C | 1 | 2006 | 390 | 0.180 |
Why?
|
| Pregnancy Outcome | 1 | 2005 | 630 | 0.180 |
Why?
|
| Immunosuppressive Agents | 1 | 2006 | 667 | 0.180 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2007 | 617 | 0.180 |
Why?
|
| Antineoplastic Agents | 2 | 2014 | 1810 | 0.180 |
Why?
|
| Retrospective Studies | 11 | 2019 | 17667 | 0.180 |
Why?
|
| Cholestasis | 1 | 2003 | 165 | 0.170 |
Why?
|
| Embolization, Therapeutic | 1 | 2003 | 224 | 0.170 |
Why?
|
| Sex Factors | 2 | 2018 | 1346 | 0.170 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2009 | 998 | 0.160 |
Why?
|
| Pregnancy Complications | 1 | 2005 | 547 | 0.160 |
Why?
|
| Necrosis | 2 | 2014 | 195 | 0.160 |
Why?
|
| Databases, Factual | 3 | 2018 | 1224 | 0.160 |
Why?
|
| Proportional Hazards Models | 2 | 2015 | 1405 | 0.160 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2020 | 334 | 0.160 |
Why?
|
| Healthy Volunteers | 1 | 2020 | 157 | 0.150 |
Why?
|
| Comorbidity | 3 | 2013 | 1600 | 0.150 |
Why?
|
| Immune System | 1 | 2020 | 98 | 0.150 |
Why?
|
| Adiposity | 1 | 2020 | 207 | 0.150 |
Why?
|
| Bilirubin | 2 | 2012 | 126 | 0.150 |
Why?
|
| Cytoskeleton | 1 | 2020 | 167 | 0.150 |
Why?
|
| Aftercare | 1 | 2019 | 154 | 0.140 |
Why?
|
| Lypressin | 1 | 2018 | 18 | 0.140 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2020 | 288 | 0.140 |
Why?
|
| Donor Selection | 1 | 2018 | 58 | 0.140 |
Why?
|
| Risk Assessment | 4 | 2018 | 3695 | 0.130 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2005 | 742 | 0.130 |
Why?
|
| Follow-Up Studies | 5 | 2019 | 5297 | 0.130 |
Why?
|
| Narcotics | 1 | 2017 | 59 | 0.130 |
Why?
|
| Drug Therapy | 1 | 2017 | 83 | 0.130 |
Why?
|
| Transplant Recipients | 1 | 2019 | 234 | 0.130 |
Why?
|
| Lipid Metabolism | 1 | 2020 | 371 | 0.130 |
Why?
|
| Drug Overdose | 1 | 2017 | 72 | 0.120 |
Why?
|
| DNA Repair | 1 | 2020 | 562 | 0.120 |
Why?
|
| Models, Biological | 2 | 2013 | 1392 | 0.120 |
Why?
|
| Oxidative Stress | 1 | 2020 | 807 | 0.120 |
Why?
|
| Proteomics | 1 | 2020 | 607 | 0.120 |
Why?
|
| Decision Support Techniques | 1 | 2018 | 298 | 0.110 |
Why?
|
| Glucose | 1 | 2020 | 848 | 0.110 |
Why?
|
| Injections, Intravenous | 1 | 2015 | 242 | 0.110 |
Why?
|
| Disease Progression | 3 | 2013 | 2206 | 0.110 |
Why?
|
| Multivariate Analysis | 2 | 2015 | 1405 | 0.110 |
Why?
|
| Models, Statistical | 1 | 2017 | 493 | 0.110 |
Why?
|
| Adolescent | 7 | 2018 | 20982 | 0.110 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2015 | 1078 | 0.110 |
Why?
|
| Factor VII | 2 | 2005 | 17 | 0.110 |
Why?
|
| Surgical Procedures, Operative | 1 | 2017 | 229 | 0.110 |
Why?
|
| Hepatitis A Virus Cellular Receptor 1 | 1 | 2014 | 4 | 0.110 |
Why?
|
| beta 2-Microglobulin | 1 | 2014 | 36 | 0.110 |
Why?
|
| Lipocalin-2 | 1 | 2014 | 28 | 0.110 |
Why?
|
| Acute-Phase Proteins | 1 | 2014 | 45 | 0.110 |
Why?
|
| Lipocalins | 1 | 2014 | 32 | 0.110 |
Why?
|
| Prognosis | 4 | 2019 | 4952 | 0.110 |
Why?
|
| Intramolecular Oxidoreductases | 1 | 2014 | 45 | 0.110 |
Why?
|
| Chi-Square Distribution | 1 | 2015 | 570 | 0.110 |
Why?
|
| Cognition | 1 | 2020 | 845 | 0.110 |
Why?
|
| Iothalamic Acid | 1 | 2013 | 4 | 0.100 |
Why?
|
| Receptors, Virus | 1 | 2014 | 97 | 0.100 |
Why?
|
| Diuretics | 1 | 2014 | 158 | 0.100 |
Why?
|
| Cohort Studies | 3 | 2014 | 5123 | 0.100 |
Why?
|
| Inflammation | 1 | 2020 | 1492 | 0.100 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2006 | 2120 | 0.100 |
Why?
|
| Drug Monitoring | 1 | 2015 | 285 | 0.090 |
Why?
|
| Membrane Glycoproteins | 1 | 2014 | 421 | 0.090 |
Why?
|
| Length of Stay | 1 | 2017 | 1399 | 0.090 |
Why?
|
| Organ Size | 1 | 2012 | 435 | 0.090 |
Why?
|
| Likelihood Functions | 1 | 2011 | 117 | 0.090 |
Why?
|
| Young Adult | 5 | 2019 | 10104 | 0.080 |
Why?
|
| Sodium | 1 | 2012 | 281 | 0.080 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2014 | 600 | 0.080 |
Why?
|
| Health Status Indicators | 1 | 2010 | 124 | 0.080 |
Why?
|
| Antiviral Agents | 2 | 2006 | 812 | 0.080 |
Why?
|
| Infant | 3 | 2010 | 13306 | 0.080 |
Why?
|
| Child, Preschool | 3 | 2010 | 15057 | 0.070 |
Why?
|
| Ribavirin | 2 | 2006 | 86 | 0.070 |
Why?
|
| Hospitalization | 1 | 2017 | 1939 | 0.070 |
Why?
|
| Prevalence | 1 | 2015 | 2694 | 0.070 |
Why?
|
| Thrombomodulin | 2 | 2005 | 18 | 0.070 |
Why?
|
| Thromboplastin | 2 | 2005 | 19 | 0.070 |
Why?
|
| Anticonvulsants | 1 | 2010 | 391 | 0.070 |
Why?
|
| Erythrocyte Indices | 1 | 2007 | 12 | 0.060 |
Why?
|
| Prothrombin Time | 1 | 2007 | 36 | 0.060 |
Why?
|
| Imatinib Mesylate | 1 | 2007 | 47 | 0.060 |
Why?
|
| Biopsy | 2 | 2012 | 1252 | 0.060 |
Why?
|
| Blood Cell Count | 1 | 2007 | 64 | 0.060 |
Why?
|
| Aged, 80 and over | 2 | 2008 | 6922 | 0.060 |
Why?
|
| Survival Analysis | 1 | 2010 | 1521 | 0.060 |
Why?
|
| Alkaline Phosphatase | 1 | 2007 | 93 | 0.060 |
Why?
|
| Aspartate Aminotransferases | 1 | 2007 | 79 | 0.060 |
Why?
|
| Logistic Models | 1 | 2011 | 1831 | 0.060 |
Why?
|
| Cholangiopancreatography, Magnetic Resonance | 1 | 2006 | 10 | 0.060 |
Why?
|
| Alanine Transaminase | 1 | 2007 | 156 | 0.060 |
Why?
|
| Benzamides | 1 | 2007 | 122 | 0.060 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2007 | 103 | 0.060 |
Why?
|
| Recurrence | 2 | 2009 | 1483 | 0.060 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 1 | 2006 | 75 | 0.060 |
Why?
|
| Polycystic Kidney, Autosomal Dominant | 1 | 2005 | 13 | 0.060 |
Why?
|
| Atrophy | 1 | 2006 | 251 | 0.060 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2006 | 165 | 0.060 |
Why?
|
| Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2005 | 24 | 0.060 |
Why?
|
| Hepatectomy | 1 | 2006 | 124 | 0.060 |
Why?
|
| Radiography, Abdominal | 1 | 2005 | 46 | 0.060 |
Why?
|
| Endoscopy, Digestive System | 1 | 2006 | 154 | 0.060 |
Why?
|
| Phlebography | 1 | 2005 | 43 | 0.060 |
Why?
|
| Factor VIII | 1 | 2005 | 51 | 0.060 |
Why?
|
| Iliac Vein | 1 | 2005 | 28 | 0.060 |
Why?
|
| von Willebrand Diseases | 1 | 2005 | 55 | 0.060 |
Why?
|
| Blood Platelets | 2 | 2004 | 315 | 0.060 |
Why?
|
| Diseases in Twins | 1 | 2005 | 90 | 0.060 |
Why?
|
| Femoral Vein | 1 | 2005 | 48 | 0.060 |
Why?
|
| Twins, Monozygotic | 1 | 2005 | 125 | 0.060 |
Why?
|
| Dissection | 1 | 2005 | 59 | 0.050 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 2004 | 67 | 0.050 |
Why?
|
| Drug Therapy, Combination | 2 | 2005 | 1170 | 0.050 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2004 | 50 | 0.050 |
Why?
|
| Cholesterol, HDL | 1 | 2006 | 394 | 0.050 |
Why?
|
| Child | 3 | 2010 | 26299 | 0.050 |
Why?
|
| Fibrinolysis | 1 | 2004 | 43 | 0.050 |
Why?
|
| Collateral Circulation | 1 | 2004 | 41 | 0.050 |
Why?
|
| Pre-Eclampsia | 1 | 2006 | 223 | 0.050 |
Why?
|
| Jaundice, Obstructive | 1 | 2003 | 5 | 0.050 |
Why?
|
| Kidney Failure, Chronic | 1 | 2012 | 943 | 0.050 |
Why?
|
| Infusions, Intravenous | 1 | 2005 | 549 | 0.050 |
Why?
|
| Catheterization | 1 | 2005 | 234 | 0.050 |
Why?
|
| International Normalized Ratio | 1 | 2003 | 46 | 0.050 |
Why?
|
| Triglycerides | 1 | 2006 | 605 | 0.050 |
Why?
|
| Platelet Count | 1 | 2003 | 140 | 0.050 |
Why?
|
| Integrins | 1 | 2003 | 90 | 0.050 |
Why?
|
| Pregnancy | 2 | 2006 | 7572 | 0.050 |
Why?
|
| Epilepsy | 1 | 2010 | 889 | 0.050 |
Why?
|
| Cause of Death | 2 | 2019 | 510 | 0.050 |
Why?
|
| Mice | 1 | 2020 | 18487 | 0.050 |
Why?
|
| Registries | 1 | 2009 | 1599 | 0.050 |
Why?
|
| Colonic Polyps | 1 | 2003 | 86 | 0.050 |
Why?
|
| Inflammation Mediators | 1 | 2003 | 226 | 0.050 |
Why?
|
| Thrombocytopenia | 1 | 2003 | 222 | 0.040 |
Why?
|
| Probability | 2 | 2014 | 310 | 0.040 |
Why?
|
| Stents | 1 | 2005 | 778 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2003 | 1234 | 0.040 |
Why?
|
| Incidence | 1 | 2006 | 3347 | 0.040 |
Why?
|
| Animals | 1 | 2020 | 34374 | 0.040 |
Why?
|
| United Kingdom | 1 | 2019 | 255 | 0.030 |
Why?
|
| Allografts | 1 | 2018 | 209 | 0.030 |
Why?
|
| Pancreatic Neoplasms | 1 | 2003 | 732 | 0.030 |
Why?
|
| Cardiovascular Diseases | 2 | 2009 | 2082 | 0.030 |
Why?
|
| Camptothecin | 1 | 2014 | 78 | 0.030 |
Why?
|
| Intensive Care Units | 1 | 2017 | 517 | 0.030 |
Why?
|
| Fluorouracil | 1 | 2014 | 134 | 0.030 |
Why?
|
| Disseminated Intravascular Coagulation | 2 | 2004 | 66 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2005 | 3917 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2018 | 2297 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2005 | 792 | 0.020 |
Why?
|
| Liver Function Tests | 1 | 2012 | 97 | 0.020 |
Why?
|
| Serum | 1 | 2012 | 45 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2018 | 2989 | 0.020 |
Why?
|
| Brain | 1 | 2003 | 3239 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2015 | 1911 | 0.020 |
Why?
|
| Sepsis | 1 | 2009 | 501 | 0.010 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2004 | 47 | 0.010 |
Why?
|
| P-Selectin | 1 | 2004 | 69 | 0.010 |
Why?
|
| Causality | 1 | 2004 | 91 | 0.010 |
Why?
|
| Interleukin-13 | 1 | 2004 | 96 | 0.010 |
Why?
|
| Cyclooxygenase 2 | 1 | 2004 | 128 | 0.010 |
Why?
|
| Thrombophilia | 1 | 2004 | 41 | 0.010 |
Why?
|
| Hemostasis | 1 | 2004 | 73 | 0.010 |
Why?
|
| Drug Carriers | 1 | 2004 | 117 | 0.010 |
Why?
|
| Annexin A5 | 1 | 2003 | 18 | 0.010 |
Why?
|
| Interleukin-8 | 1 | 2004 | 207 | 0.010 |
Why?
|
| E-Selectin | 1 | 2003 | 39 | 0.010 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2003 | 121 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2012 | 3834 | 0.010 |
Why?
|
| Viral Load | 1 | 2004 | 406 | 0.010 |
Why?
|
| Hepacivirus | 1 | 2004 | 273 | 0.010 |
Why?
|
| Reference Values | 1 | 2003 | 692 | 0.010 |
Why?
|
| Stress, Physiological | 1 | 2003 | 262 | 0.010 |
Why?
|
| Colonoscopy | 1 | 2003 | 247 | 0.010 |
Why?
|
| Hemorrhage | 1 | 2004 | 498 | 0.010 |
Why?
|
| Myocardium | 1 | 2004 | 874 | 0.010 |
Why?
|
| Thrombosis | 1 | 2004 | 495 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2003 | 2143 | 0.010 |
Why?
|
| Membrane Proteins | 1 | 2004 | 1613 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2003 | 3454 | 0.010 |
Why?
|